Carna Biosciences, Inc., BMA 3F, 1-5-5 Minatojima-minamimachi, Chuo-ku, Kobe 650-0047, Japan.
Carna Biosciences, Inc., BMA 3F, 1-5-5 Minatojima-minamimachi, Chuo-ku, Kobe 650-0047, Japan.
Bioorg Med Chem Lett. 2021 Jul 1;43:128056. doi: 10.1016/j.bmcl.2021.128056. Epub 2021 Apr 21.
p38α mitogen activated protein kinase (MAPK) plays important roles in multiple cellular functions by phosphorylating a wide variety of substrates, and therefore, p38α MAPK has been considered as an important drug target. In this study, we designed peptide-based inhibitors for p38α MAPK, which can only inhibit the Smad3 phosphorylation specifically, by targeting the KIM binding site of p38α MAPK. Peptide 6 showed a significant inhibitory potency for the Smad3 phosphorylation by p38α MAPK. Peptide 6 showed no ATP dependency, and did not inhibit the phosphorylation of other substrates by p38α MAPK. The discovery of peptide 6 by targeting the KIM binding site likely provide an opportunity for the discovery of a novel class of allosteric and substrate-specific p38α MAPK inhibitors.
p38α 丝裂原活化蛋白激酶(MAPK)通过磷酸化多种底物在多种细胞功能中发挥重要作用,因此,p38α MAPK 已被视为重要的药物靶标。在这项研究中,我们设计了针对 p38α MAPK 的基于肽的抑制剂,通过靶向 p38α MAPK 的 KIM 结合位点,这些抑制剂只能特异性抑制 Smad3 磷酸化。肽 6 对 p38α MAPK 诱导的 Smad3 磷酸化具有显著的抑制作用。肽 6 不依赖于 ATP,也不抑制 p38α MAPK 对其他底物的磷酸化。通过靶向 KIM 结合位点发现肽 6,可能为发现新型别构和底物特异性 p38α MAPK 抑制剂提供了机会。